Tam C - Search Results

1

Prognostic factors in chronic lymphocytic leukaemia - the old, the new and the future.

McKeague S, Tam C. McKeague S, et al. Among authors: tam c. Leuk Lymphoma. 2025 Jan 7:1-11. doi: 10.1080/10428194.2024.2449214. Online ahead of print. Leuk Lymphoma. 2025. PMID: 39773307 Review.

2

SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions.

Bennett R, Thompson E, Tam C. Bennett R, et al. Among authors: tam c. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):795-804. doi: 10.1016/j.clml.2022.07.013. Epub 2022 Jul 23. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35970756 Free article. Review.

3

How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?

Tam CS, Stilgenbauer S. Tam CS, et al. Leuk Lymphoma. 2015 Mar;56(3):587-93. doi: 10.3109/10428194.2015.1011641. Epub 2015 Feb 17. Leuk Lymphoma. 2015. PMID: 25641428 Review.

4

Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy.

Lew TE, Cheah CY, Carney DA, Prince HM, Wolf M, Bazargan A, Januszewicz EH, Filshie R, Westerman D, Seymour JF, Tam CS. Lew TE, et al. Leuk Lymphoma. 2016 May;57(5):1044-53. doi: 10.3109/10428194.2015.1096353. Epub 2015 Nov 20. Leuk Lymphoma. 2016. PMID: 26464106

5

New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents.

Bazargan A, Tam CS. Bazargan A, et al. Leuk Lymphoma. 2010 Sep;51(9):1596-611. doi: 10.3109/10428194.2010.497885. Leuk Lymphoma. 2010. PMID: 20578824 Review.

6

Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence?

Tam CS, Keating MJ. Tam CS, et al. Leuk Lymphoma. 2013 May;54(5):934-9. doi: 10.3109/10428194.2012.728595. Epub 2012 Sep 28. Leuk Lymphoma. 2013. PMID: 22966877 Review.

7

Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.

Mulligan SP, Opat S, Cheah CY, Kuss B, Hertzberg M, Marlton P, Poplar S, Puig A, McGeachie M, Weinkove R, Tam CS. Mulligan SP, et al. Leuk Lymphoma. 2023 Feb;64(2):312-318. doi: 10.1080/10428194.2022.2148220. Epub 2022 Nov 24. Leuk Lymphoma. 2023. PMID: 36423351 Free article.

8

Defining the appropriate starting dose of lenalidomide in chronic lymphocytic leukemia: remember the old fable of the hare and the tortoise.

Tam CS, Polliack A. Tam CS, et al. Leuk Lymphoma. 2016;57(6):1247-8. doi: 10.3109/10428194.2015.1137294. Epub 2016 Feb 17. Leuk Lymphoma. 2016. PMID: 26732524 No abstract available.

9

New agents for the treatment of genetically high-risk chronic lymphocytic leukemia.

Bazargan A, Tam CS. Bazargan A, et al. Leuk Lymphoma. 2010 Jan;51(1):3-4. doi: 10.3109/10428190903499702. Leuk Lymphoma. 2010. PMID: 20001866 No abstract available.

10

Immune impacts of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia patients: are we closer to a holy grail?

Handunnetti SM, Tam CS. Handunnetti SM, et al. Leuk Lymphoma. 2020 Oct;61(10):2283-2285. doi: 10.1080/10428194.2020.1811865. Epub 2020 Sep 8. Leuk Lymphoma. 2020. PMID: 32900243 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,451 results

Search Page

Filters